Słowa kluczowe
onkologia
radioimmunoterapia
Jak cytować
Abstrakt
Radioimmunoterapia (z ang. radioimmunotherapy; RIT) jest metodą leczenia ukierunkowanego biologicznie, wykorzystywaną u chorych z rozpoznanym chłoniakiem nieziarnicznym z komórek B (z ang. non-Hodgkin lymphoma, NHL). RIT może być stosowany jest jako metoda pierwszego rzutu, a także element leczenia skojarzonego z chemioterapią. Pomimo uznanej skuteczności w leczeniu NHL, RIT jest rzadko stosowana.
Bibliografia
Dostęp w Internecie: Globocan 2018, Cancer Fact Sheets. Ferlay J, Ervik M, Lam F, Colombet M, Mery L, Piñeros M, Znaor A, Soerjomataram I, Bray F (2018). Global Cancer Observatory: Cancer Today. Lyon, France: International Agency for Research on Cancer. http://gco.iarc. https://gco.iarc.fr/today. Data ostatniej aktualizacji: 01.1.2020.
Younes A. Handbook of Lymphoma. Springer, 2016. ISBN 978-3-319-08467.
Evans A M, Blum K A, Non-Hodgkin Lymphoma. Patology, Imaging and Current Therapy. Springer, 2015. ISBN 978-3-319-13150-4.
Marcus R, Sweetenham J W, Williams M. Lymphoma. Pathology, Diagnosis and Treatment. Second Edition. Cambridge, Cambridge University Press, 2014.
ISBN 978-1-107-01059-8.
Cheson B D, Fisher R I, Barrington S F. Recommendations for Initial Evaluation, Staging, and Response Assessment of Hodgkin and Non-Hodgkin Lymphoma:
The Lugano Classification. Clin. Oncol. 2014; 32: 3059–3068.
Swerdlow S H, Campo E, Harris N L. WHO Classification of Tumours of Haematopoietic nad Lymphoid Tissues. Revised 4th Edition. Lyon, IARC, 2016. ISBN 978-92-835-4494-3.
Sachpekidis C, Jackson D B, Soldatos T G. Radioimmunotherapy in Non-Hodgkin’s Lymphoma: Retrospective Adverse Event Profiling of Zevalin and Bexxar. Pharmaceuticals 2019, 12(4), 141.
Huang G. Nuclear Medicine in Oncology. Molecular Imaging and Target Therapy. Springer, 2019. ISBN 978-981-13-7458-6.
Giovanella L. Nuclear Medicine Therapy. Side Effects and Complications. Springer, 2019. ISBN 978-3-030-17494-1.
Schlechter B L, Kim M S, Joyce R M. An update on radioimmunotherapy for lymphoma. J. Hematol. Oncol 2013, 2(2), 163–178.
Aktolun C, Goldsmith S J. Nuclear Medicine Therapy. Principles and Clinical Applications. Springer, 2013. ISBN 978-1-4614-4021-5.
Schimoni A, Zwas S T. Radioimmunotherapy and Autologous Stem-Cell Transplantation in the Treatment of B-Cell Non-Hodgkin Lymphoma. Seminars in nuclear medicine 2016, 46(2):119-125.
Bombardieri E, Seregni E, Evangelista L, Chiesa C, Chiti A. Clinical Applications of Nuclear Medicine Targeted Therapy. Springer 2018. ISBN 978-3-319-63067-0.
Eskian M, Khorasanizadeh M, Zinzani M P, Rezaei N. Radioimmunotherapy as the first line of treatment in non-Hodgkin lymphoma. Immunotherapy 2018; 10(8):
-711.
Regan P M, Friedberg J W. Advancing radioimmunotherapy and its future role in non-Hodgkin lymphoma. Future Oncology 2015, 11(10):1543-53.
Kitajima K, Okada M, Kashiwagi T, Yoshihara K, Tokugawa T , Sawada A, Yoshihara S, Fujimori Y, Yamakado K. Early evaluation of tumor response to
Y-ibritumomab radioimmunotherapy in relapsed/refractory B cell non-Hodgkin lymphoma: what is the optimal timing for FDG-PET/CT?. Europen Radiology 2019, 29(7):3935-3944.
Repetto‐Llamazares A H V, Malenge M M, O'Shea A, Eiríksdóttir B, Stokke T, Larsen R H, Dahle J. Combination of 177Lu‐lilotomab with rituximab significantly improves the therapeutic outcome in preclinical models of non‐Hodgkin's lymphoma.